Applied DNA Sciences (APDN) Granted FDA Emergency Use Authorization for COVID-19 Diagnostic Assay Kit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Applied DNA Receives FDA Emergency Use Authorization for COVID-19 Diagnostic Assay Kit
May 14, 2020 5:00 AM EDT- Advanced Single Well Assay Designed for High-Throughput Testing -
STONY BROOK, N.Y.--(BUSINESS WIRE)-- Applied DNA Sciences Inc. (NASDAQ: APDN) (Applied DNA or the Company, our) announced today that the U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for the clinical use of the Companys patent-pending Linea COVID-19 RT-PCR test for COVID-19. Clinical laboratories in the United States certified under Clinical Laboratory Improvement Amendments (CLIA) to perform hi complexity tests. CLIA labs can immediately begin ordering and using the Linea COVID-19 assay... More
